<DOC>
	<DOCNO>NCT00770744</DOCNO>
	<brief_summary>The main purpose study explore efficacy safety Lu 31-130 patient suffer schizophrenia compare standard antipsychotic drug .</brief_summary>
	<brief_title>Efficacy Lu 31-130 Patients With Schizophrenia</brief_title>
	<detailed_description>Schizophrenia serious disable mental disorder affect approximately 1 % world 's population . Antipsychotic drug remain cornerstone pharmacotherapy schizophrenia . However , none available drug ideal , particular complex safety profile limited effectiveness certain symptom domain . Whereas positive symptom respond treatment effect negative symptom cognitive impairment modest . Thus present treatment option leave room improvement call new , effective pharmacotherapies treatment schizophrenia . In current study , patient suffer schizophrenia experience clinically significant symptom disease include . Eligible patient randomise blind treatment either flexible dos Lu 31-130 flexible dos standard antipsychotic treatment ( olanzapine ) 12 week . The efficacy ( include potential effect cognitive symptom ) safety Lu 31-130 explore comparison olanzapine .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>The subject primary diagnosis schizophrenia The subject experience clinically significant symptom The subject willing hospitalized initial period study The subject normal serum value parameter associate liver function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Antipsychotic</keyword>
	<keyword>Olanzapine</keyword>
	<keyword>Lu 31-130</keyword>
</DOC>